🏛️ Verified NIH Record • Updated 2026-07-08
A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy (NCT03779334)
An Open-Label Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Hoffmann-La Roche
🩺 Plain-English Summary (8th-Grade Level)
A global study of oral risdiplam in pre-symptomatic participants with spinal muscular atrophy (SMA).
Who can join: Review the eligibility criteria below.
Location: Nemours Children's Hospital — Orlando, Florida
Age range: 1 Day to 6 Weeks
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (7 Sites)
- Nemours Children's Hospital — Orlando, Florida
- Sydney Children's Hospital — Randwick, New South Wales
- Chr de La Citadelle — Liège,
- Hospital das Clinicas - FMUSP_X — São Paulo, São Paulo
- Szpital Gdanskiego Uniwersytetu Medycznego — Gda?sk,
- Russian Children Neuromuscular Center of Veltischev — Moscow, Moscow Oblast
- Kaohsiung Medical University Chung-Ho Hospital — Kaohsiung City,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Muscular Atrophy, Spinal
- A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy — Little Rock, Arkansas
- A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy — Little Rock, Arkansas
- A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK) — Orange, California
- A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec — Flower Mound, Texas
- A Study to Learn How Nusinersen (Spinraza) Affects Participants With Spinal Muscular Atrophy (SMA) Who Took it Before or During Pregnancy And About The Health of Their Babies — Palo Alto, California
Explore by condition: All Muscular Atrophy, Spinal clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.